The anti-phospholipid antibody syndrome (Hughes syndrome): Therapeutic aspects

Bailliere's Best Practice and Research in Clinical Rheumatology

Volumn 14, Issue 1, 2000, Pages 151-163

  Cuadrado, Maria J ^a   Khamashta, Munther A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anti cardiolipin antibodies; Foetal loss; Lupus anti coagulant; Thromboprophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; CARDIOLIPIN ANTIBODY; CHLOROQUINE; CORTICOSTEROID; DANAZOL; DAPSONE; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; HUMAN; ORAL CONTRACEPTION; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; SPLENECTOMY; STROKE; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034094985     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.1999.0083     Document Type: Article

References (50)

1. Wilson W A, Gharavi A E, Koike T. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis and Rheumatism. 42:1999;1309-1311.
2. Love P E, Santoro S A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Annals of Internal Medicine. 112:1990;682-698.
3. Neurology. 43:1993;2069-2073.
4. Ginsburg K S, Liang M H, Newcome L. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Annals of Internal Medicine. 117:1992;997-1002.
5. Finazzi G, Brancaccio V, Moia M. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian registry. American Journal of Medicine. 100:1996;530-536.
6. Vaarala O, Mänttäri M, Manninen V. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 91:1995;23-27.
7. Silver R M, Draper M L, Scott J R. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstetrics and Gynecology. 83:1994;372-377.
8. Shah N, Khamashta M A, Atsumi T, Hughes G RV. Outcome of patients with anticardiolipin antibodies: a 10 years follow-up of 52 patients. Lupus. 7:1998;3-6.
9. Lancet. 351:1998;233-241.
10. Wallace D J, Linker-Israeli M, Metzger A I, Stecher V J. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 2:1993;S13-S15.
11. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis. Lupus. 5:1996;S16-S22.
12. Bern M M, Lokich J J, Wallach S R. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Annals of Internal Medicine. 112:1990;423-428.
13. Levine M, Hirsh J, Gent M. Double-blind randomised trial of very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 343:1994;886-889.
14. Rosove M H, Brewer P MC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Annals of Internal Medicine. 117:1992;303-308.
15. Khamashta M A, Cuadrado M J, Mujic F. The management of thrombosis in the antiphospholipid antibody syndrome. New England Journal of Medicine. 332:1995;993-997.
16. Krnic-Barrie S, O'Connor C R, Looney S W, Pierangeli S S, Harris E N. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Archives of Internal Medicine. 157:1997;2101-2108.
17. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. American Journal of Medicine. 104:1998;332-338.
18. Kearon C, Gent M, Hirsch J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New England Journal of Medicine. 340:1999;901-907.
19. Ginsberg J S, Wells P S, Brill-Edwards P. Antiphospholipid antibodies and venous thromboembolism. Blood. 86:1995;3685-3691.
20. Meade T W, Miller G J. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at risk. American Journal of Cardiology. 75:1995;23B-26B.
21. Hughes G RV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. British Medical Journal. 287:1983;1088-1099.
22. Palareti G, Leali N, Cocheri S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian study on complications of oral anticoagulant therapy. Lancet. 348:1996;423-428.
23. Al-Sayegh F A, Ensworth S, Huang S, Stein H B, Kinkhoff A V. Hemorrhagic complications of long-term anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. Journal of Rheumatology. 24:1997;1716-1718.
24. Piette J C, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation. 97:1998;2195-2196.
25. Ravelli A, Martini A. Antiphospholipid antibody syndrome in pediatric patients. Rheumatic Disease Clinics of North America. 23:1997;657-676.
26. Moll S, Ortel T L. Monitoring warfarin therapy in patients with lupus anticoagulants. Annals of Internal Medicine. 127:1997;177-185.
27. Lawrie A S, Purdy G, Mackie I J, Machin S J. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the antiphospholipid syndrome. British Journal of Haematology. 98:1997;887-892.
28. Asherson R A, Cervera R, Piette J C. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore). 77:1998;195-207.
29. Cuadrado M J, Mujic F, Munoz E, Khamashta M A, Hughes G RV. Thrombocytopenia in the antiphospholipid syndrome. Annals of the Rheumatic Diseases. 56:1997;194-196.
30. Galindo M, Khamashta M A, Hughes G RV. Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome. Rheumatology. 38:1999;848-853.
31. Lima F, Khamashta M A, Buchanan N MM. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clinical and Experimental Rheumatology. 14:1996;131-136.
32. Langford K, Nelson-Piercy C. Antiphospholipid syndrome in pregnancy. Contemporary Reviews in Obstetrics and Gynaecology. 11:1999;93-98.
33. Balasch J, Carmona F, Lopez-Soto A. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Human Reproduction. 8:1993;2234-2239.
34. Krause I, Blank M, Gilbrut B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. American Journal of Reproductive Immunology. 29:1993;155-161.
35. Hunt B J, Khamashta M A, Lakasing L. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable? Thrombosis and Haemostasis. 79:1998;1060-1061.
36. Laskin C A, Bombardier C, Hannah M E. Prednisolone and aspirin in women with antibodies and unexplained recurrent fetal loss. New England Journal of Medicine. 337:1997;148-153.
37. Cowchock F S, Reece E A, Balaban D, Branch D W, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisolone with low-dose heparin treatment. American Journal of Obstetrics and Gynecology. 166:1992;1318-1323.
38. Nelson-Piercy C, Letsky E A, de Swiet M. Low-molecular-weight heparin for obstetric prophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. American Journal of Obstetrics and Gynecology. 176:1997;1062-1068.
39. Khamashta M A, Mackworth-Young C. Antiphospholipid (Hughes') syndrome. A treatable cause of recurrent pregnancy loss. British Medical Journal. 314:1997;244.
40. Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology. 174:1996;1584-1589.
41. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant humans with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal. 314:1997;253-257.
42. Gordon C, Kilby M D. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 7:1998;429-433.
43. Branch D W, Hatasaka H H. Antiphospholipid antibodies and infertility: fact or fallacy. Lupus. 7:1998;S90-S94.
44. Ijdo J W, Conti-Kelly A M, Greco P. Antiphospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus. 8:1999;109-115.
45. Khamashta M A, Cervera R, Asherson R. Association of antibodies against phsopholipids with heart valve disease in systemic lupus erythematosus. Lancet. 335:1990;1541-1544.
46. Zahavi J, Charach G, Schafer R, Toeg A, Zahavi M. Ischemic necrotic toes associated with the antiphospholipid syndrome and treated with iloprost. Lancet. 342:1993;862.
47. Sandoval J, Amigo M C, Barragan R. Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy. Journal of Rheumatology. 23:1996;772-775.
48. Radhakrishnan J, Williams G C, Appel G B, Cohen D J. Renal transplantation in anticardiolipin antibody-positive lupus eyrthematosus patients. American Journal of Kidney Diseases. 23:1994;286-289.
49. Gertner E, Lie J T. Systemic therapy with fibrinolytic agents and heparin for recalcitrant non-healing cutaneous ulcer in the antiphospholipid syndrome. Journal of Rheumatology. 21:1994;2159-2161.
50. Gomez-Pacheco L, Villa A R, Drenkard C. Serum anti-β2-glycoprotein I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. American Journal of Medicine. 106:1999;417-423.